R. Rakhimov, A. V. Sultanbaev, K. Menshikov, A. Nasretdinov, S. Musin, O. Lipatov, V. A. Suravatkin
{"title":"在实际临床实践中，来伐替尼和依维莫司联合治疗靶向治疗耐药的转移性肾细胞癌患者的有效性","authors":"R. Rakhimov, A. V. Sultanbaev, K. Menshikov, A. Nasretdinov, S. Musin, O. Lipatov, V. A. Suravatkin","doi":"10.33667/2078-5631-2024-7-18-25","DOIUrl":null,"url":null,"abstract":"Every year, 400,000 new cases of renal cell carcinoma (RCC) and 175,000 deaths are registered worldwide. Currently available advanced treatments for RCC have less toxicity than previously used therapeutic agents, but drug resistance remains a clinically significant problem. Drug resistance occurs as a result of angiogenic transition through activation of pathways that do not depend on VEGF targets of most first-line treatments. Lenvatinib with everolimus can fight resistance to increase both progression-free survival and overall survival in patients with metastatic RCC according to clinical studies.","PeriodicalId":18337,"journal":{"name":"Medical alphabet","volume":" 12","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effectiveness of the combination of lenvatinib and everolimus in metastatic renal cell carcinoma in patients with resistance to targeted treatment in real clinical practice\",\"authors\":\"R. Rakhimov, A. V. Sultanbaev, K. Menshikov, A. Nasretdinov, S. Musin, O. Lipatov, V. A. Suravatkin\",\"doi\":\"10.33667/2078-5631-2024-7-18-25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Every year, 400,000 new cases of renal cell carcinoma (RCC) and 175,000 deaths are registered worldwide. Currently available advanced treatments for RCC have less toxicity than previously used therapeutic agents, but drug resistance remains a clinically significant problem. Drug resistance occurs as a result of angiogenic transition through activation of pathways that do not depend on VEGF targets of most first-line treatments. Lenvatinib with everolimus can fight resistance to increase both progression-free survival and overall survival in patients with metastatic RCC according to clinical studies.\",\"PeriodicalId\":18337,\"journal\":{\"name\":\"Medical alphabet\",\"volume\":\" 12\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical alphabet\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33667/2078-5631-2024-7-18-25\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical alphabet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33667/2078-5631-2024-7-18-25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The effectiveness of the combination of lenvatinib and everolimus in metastatic renal cell carcinoma in patients with resistance to targeted treatment in real clinical practice
Every year, 400,000 new cases of renal cell carcinoma (RCC) and 175,000 deaths are registered worldwide. Currently available advanced treatments for RCC have less toxicity than previously used therapeutic agents, but drug resistance remains a clinically significant problem. Drug resistance occurs as a result of angiogenic transition through activation of pathways that do not depend on VEGF targets of most first-line treatments. Lenvatinib with everolimus can fight resistance to increase both progression-free survival and overall survival in patients with metastatic RCC according to clinical studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
